MEK1/2 inhibition ameliorates clinical lesions in experimental pemphigus vulgaris
Molecular Therapy · 2026-11
DOI: 10.1016/j.ymthe.2026.10.034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026-11. Verfasst von Shirin Emtenani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Luebeck Institute of Experimental Dermatology, University of Luebeck, 23562, Luebeck, Germany. Electronic address: shirin.emtenani@uksh.de. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Scholarship Council, German Research Foundation, University of Lubeck.
Abstract (Originalsprache)
Pemphigus vulgaris (PV) is a life-threatening autoimmune blistering disease primarily driven by autoantibodies targeting desmoglein 3 (Dsg3), resulting in loss of keratinocyte cohesion and clinically manifesting blisters and erosions of surface-close mucosal tissues. Current therapies suppress autoantibody production but fail to directly restore desmosomal adhesion. Here, we established an adult mouse model of PV through repeated injections of AK47ch, a recombinant monospecific anti-Dsg3 IgG1 antibody, into C57BL/6J mice. Within 12 days, AK47ch-treated mice reproducibly developed hallmark features of PV, including oral lesions, patchy alopecia, suprabasal acantholysis confined to mucosal tissues, and intercellular IgG deposition. Prophylactic and quasi-therapeutic intravenous immunoglobulin (IVIg), an established therapy for refractory PV, significantly reduced disease progression. The selective MEK1/2 inhibitor selumetinib, previously shown to block anti-Dsg3 IgG-induced keratinocyte dissociation in vitro, attenuated disease severity in clinically affected mice and reduced MEK1/2 phosphorylation in lesional mucosa. MEK1/2 inhibition was associated with reduced expression of transcripts linked to inflammatory, chemokine, cytokine, and interferon responses, and increased expression of transcripts related to cellular homeostasis, as shown by targeted NanoString nCounter analysis of buccal mucosa biopsies. This model provides a platform for preclinical evaluation of desmosome-stabilizing therapies and identifies the MEK/ERK signaling axis as a pharmacologically actionable target in PV.
Autor:innen und Institutionen
- Luebeck Institute of Experimental Dermatology, University of Luebeck, 23562, Luebeck, Germany. Electronic address: shirin.emtenani@uksh.de.
- Luebeck Institute of Experimental Dermatology, University of Luebeck, 23562, Luebeck, Germany.
- Vegetative Anatomy, Institute of Anatomy, LMU Medizin, Ludwig-Maximilians-Universität München, 80336, Munich, Germany.
- Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, 23560, Luebeck, Germany.
- Luebeck Institute of Experimental Dermatology, University of Luebeck, 23562, Luebeck, Germany; Department of Dermatology, University Hospital Schleswig-Holstein, Campus Luebeck, 23562, Luebeck, Germany. Electronic addre…
Förderung
- China Scholarship Council
- German Research Foundation
- University of Lubeck
Zitieren
APA
Emtenani, S., Patzelt, S., Zarabadi, K., Yang, T., Sigmund, A. M., Hofrichter, M., Probst, C., Waschke, J., & Schmidt, E. (2026). MEK1/2 inhibition ameliorates clinical lesions in experimental pemphigus vulgaris. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.10.034
Vancouver
Emtenani S, Patzelt S, Zarabadi K, Yang T, Sigmund AM, Hofrichter M, et al. MEK1/2 inhibition ameliorates clinical lesions in experimental pemphigus vulgaris. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.10.034
BibTeX
@article{Emtenani2026,
author = {Emtenani, Shirin and Patzelt, Sabrina and Zarabadi, Kiana and Yang, Tingyu and Sigmund, Anna M and Hofrichter, Maxi and Probst, Christian and Waschke, Jens and Schmidt, Enno},
title = {MEK1/2 inhibition ameliorates clinical lesions in experimental pemphigus vulgaris},
journal = {Molecular Therapy},
year = {2026},
doi = {10.1016/j.ymthe.2026.10.034}
}
EUVIMED